Group Iv Gp Lp Column Purchases 89,200 Shares of Eikon Therapeutics (NASDAQ:EIKN) Stock

Posted by Francis Steltz on Sep 10th, 2026

Eikon Therapeutics, Inc. (NASDAQ:EIKN – Get Free Report) major shareholder Group Iv Gp Lp Column bought 89,200 shares of Eikon Therapeutics stock in a transaction that occurred on Thursday, September 3rd. The stock was bought at an average price of $11.56 per share, with a total value of $1,031,152.00. Following the purchase, the insider owned 89,200 shares of the company’s stock, valued at $1,031,152. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Eikon Therapeutics Stock Up 0.2%

EIKN stock opened at $10.73 on Thursday. Eikon Therapeutics, Inc. has a twelve month low of $7.90 and a twelve month high of $17.40. The company has a market cap of $581.24 million and a PE ratio of -2.62. The business’s 50-day simple moving average is $10.52 and its 200 day simple moving average is $10.85.

Eikon Therapeutics (NASDAQ:EIKN – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.63) EPS for the quarter, missing the consensus estimate of ($1.61) by ($0.02). On average, equities research analysts anticipate that Eikon Therapeutics, Inc. will post -7.18 EPS for the current year.

Institutional Investors Weigh In On Eikon Therapeutics

Large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp acquired a new stake in shares of Eikon Therapeutics during the 2nd quarter worth about $624,000. Deutsche Bank AG bought a new stake in Eikon Therapeutics during the second quarter worth about $281,000. BlackRock Inc. grew its stake in Eikon Therapeutics by 29.0% during the second quarter. BlackRock Inc. now owns 4,281,425 shares of the company’s stock worth $55,873,000 after buying an additional 962,046 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Eikon Therapeutics by 23.5% during the second quarter. The Manufacturers Life Insurance Company now owns 35,357 shares of the company’s stock worth $461,000 after buying an additional 6,734 shares in the last quarter. Finally, Legal & General Group Plc bought a new position in shares of Eikon Therapeutics in the second quarter valued at approximately $28,000.

Wall Street Analyst Weigh In

EIKN has been the topic of a number of analyst reports. Wedbush lowered their target price on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating on the stock in a research note on Friday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eikon Therapeutics in a report on Friday, August 21st. Mizuho upgraded Eikon Therapeutics to a “strong-buy” rating in a research note on Monday. Finally, Weiss Ratings raised Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Eikon Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

View Our Latest Report on EIKN

About Eikon Therapeutics

(Get Free Report)

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.